736 | EFFICACY OF DOSE ESCALATION TO BEACOP‐DAC VERSUS CONTINUATION OF ABVD IN HODGKIN’S LYMPHOMA PATIENTS WITH INTERIM PET DEAUVILLE SCORE OF 4

Documenti analoghi

• 727 | DO PATIENTS WITH CLASSIC HODGKIN LYMPHOMA TREATED WITH ABVD IN LOW‐MIDDLE INCOME COUNTRIES HAVE A HIGHER RISK OF NEUTROPENIA/FEBRILE NEUTROPENIA WITHOUT G‐CSF SUPPORT?
  di: B. F. C. Galvão, et al.
  Pubblicazione: (2025)
• 722 | HODGKIN LYMPHOMA: ARE WE LEAVING PATIENTS IN “CHECK”?
  di: I. O. Ramos, et al.
  Pubblicazione: (2025)
• 863 | RADIOTHERAPY IN PREGNANT PATIENTS WITH HODGKIN’S LYMPHOMA: CLINICAL OUTCOMES AND DOSIMETRIC ASSESSMENT
  di: E. Wojciechowska‐Lampka, et al.
  Pubblicazione: (2025)
• 730 | RESULTS OF PROSPECTIVE OBSERVATIONAL STUDY OF PEMBOLIZUMAB BIOSIMILAR BCD‐201 IN PATIENTS WITH REFRACTORY CLASSICAL HODGKIN’S LYMPHOMA
  di: E. A. Gracia Medina, et al.
  Pubblicazione: (2025)
• 513 | PROGNOSTIC PREDICTIVE VALUE OF BASELINE 18F‐FDG PET/CT METABOLIC PARAMETERS IN HODGKIN’S LYMPHOMA
  di: H. Zhang, et al.
  Pubblicazione: (2025)